Celcuity Inc. is rated a Buy following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its rapid inclusion in NCCN Category 1 guidelines, which reduce risks for clinical and commercial adoption. The company has made significant upfront commercial investments, reflected in increased SG&A expenses, but its strong $754 million cash position supports operations through 2029. Positive VIKTORIA-1 trial results demonstrate improved efficacy and tolerability, encouraging quick physician uptake and positioning the drug as a potential blockbuster. Despite a high valuation at 113.8x forward EV/sales, the stock price reflects expectations for successful launch execution, label expansion, and significant earnings growth, though it leaves little margin for underperformance.
Yvonne Wassenaar, a director at Rubrik, sold 721 shares at a price of $75 each just before the company's stock experienced a significant rally. This sale occurred ahead of the stock's upward movement, which may be of interest to investors tracking in...
U.S. consumer sentiment fell sharply in August to 51, below expectations and July's 55.2, signaling growing economic concerns. Inflation expectations for the year ahead rose slightly to 4.3%, while long-term expectations remained steady but above his...
The First Trust RBA American Industrial Renaissance ETF (AIRR) focuses on small and mid-cap industrial companies involved in wiring, cooling, and powering hyperscale data centers. Its top holdings, including Comfort Systems, Sterling Infrastructure, ...
MidCap Financial Investment (MFIC) continues to experience a decline in its net asset value (NAV) and a shrinking portfolio, with total assets dropping from $3.46 billion to $2.86 billion year-over-year. Although MFIC maintains a stable dividend yiel...
Shares of Intuitive Machines surged 10% despite missing Q2 revenue and earnings estimates, driven by a record backlog of $1.8 billion and strong bookings. Virgin Galactic also gained 10% after bouncing back from a recent 8% drop caused by a delay in ...
